Relationships between mean platelet volume and serum uric acid in patients with ST-segment elevation myocardial infarction
ZHANG Ruixue1,YAN Feng1, SUN Xipeng2
1.Department of Rheumatology, the First Hospital of Tsinghua University, Beijing 100016, China; 2. Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China
Abstract：Objective To investigate the relationships between the mean platelet volume (MPV) and serum uric acid (UA) levels in patients with ST-segment elevation myocardial infarction (STEMI).Methods A total of 322 patients with STEMI were enrolled in this study between February 2016 and March 2018 in Xuanwu Hospital, with an average age of (62.74±11.60)years old. These STEMI patients were divided into the hyperuricemia (HUA) group (n=66) and normal UA group (n=256) according to serum uric acid levels. Pearson analysis was used to analyze the relationships between the MPV and UA levels. Also, multivariate linear regression and Logistic regression were performed to analyze the correlations between the MPV and UA levels in STEMI patients.Results Age, body mass index (BMI), white blood cells (WBC), MPV, serum creatinine (SCr),and blood urea nitrogen (BUN) in HUA group were significantly above those in the normal UA group with a P-value less than 0.05. Pearson analysis showed that the MPV was positively correlated with UA levels (r=0.448, P=0.000). Multivariate regression analysis showed that BMI, red blood cells (RBC), MPV, SCr, BUN and triglyceride (TG) were positively correlated with UA levels (P＜0.05). Logistic regression analysis showed that the MPV (OR=2.415, 95%CI 1.681-3.470, P=0.000) was an independent risk factor for serum UA levels.Conclusions The MPV in STEMI patients is positively correlated with UA, and may be one of the risk factors for HUA in STEMI patients.
Nozari Y, Parsa M, Jalali A,et al. Mean platelet volume and major adverse cardiac events following percutaneous coronary intervention [J]. Arch Iran Med, 2019, 22(4): 198-203.
Cortese F, Giordano P, Scicchitano P,et al. Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects [J].Vascul Pharmacol, 2019, 120: 106565.
[5]
Ndrepepa G. Uric acid and cardiovascular disease [J].Clin Chim Acta, 2018, 484: 150-163.
Kamińska J, Koper O M, Siedlecka-Czykier E,et al. The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes [J]. Saudi J Biol Sci, 2018, 25(7): 1263-1271.
Alvitigala B Y, Azra M A F, Kottahachchi D U,et al. A study of association between platelet volume indices and ST elevation myocardial infarction [J]. Int J Cardiol Heart Vasc, 2018, 21: 7-10.
[14]
Mangiacapra F, Barbato E. Clinical implications of platelet-vessel interaction [J]. J Cardiovasc Transl Res, 2013, 6(3): 310-315.
[15]
Nardin M, Verdoia M, Barbieri L,et al. Impact of metabolic syndrome on mean platelet volume and its relationship with coronary artery disease [J]. Platelets, 2019, 30(5): 615-623.
[16]
Sharaf El Din U A A, Salem M M, Abdulazim D O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review [J]. J Adv Res, 2017, 8(5): 537-548.
Budzianowski J, Pieszko K, Burchardt P,et al. The role of hematological indices in patients with acute coronary syndrome[J]. Dis Markers, 2017,2017: 3041565.
[20]
Gao X M, Moore X L, Liu Y, et al. Splenic release of platelets contributes to increased circulating platelet size and inflammation after myocardial infarction [J]. Clin Sci, 2016, 130(13): 1089-1104.
2019, Vol. 30 
